1 Study Matches
Phase 1/2 Study to Evaluate Palbociclib (IBRANCE®) in Combination with Irinotecan and Temozolomide and/or in Combination with Topotecan and Cyclophosphamide in Pediatric Patients with Recurrent or Refractory Solid Tumors
A study of the safety of palbociclib with irinotecan and temozolomide and palbociclib with topotecan and cyclophosphamide for children with solid tumors that returned or did not respond to previous treatment.
Inclusion Criteria:Have a solid tumor that has returned or did not respond to previous treatment
Ages ≥2 and <21
Exclusion Criteria:Prior intolerability to the chemo drugs used in this study